2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.13 Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US

P4.11E.13 Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US

Back to course

Pdf Summary

This study focuses on the real-world treatment patterns, healthcare costs, and resource utilization in first-line (1L) treatment of metastatic non-small cell lung cancer (NSCLC) in the US for patients with non-actionable genetic alterations. The retrospective study, examining patient data from 2016 to 2023, involved 15,659 individuals who received systemic anti-cancer treatment (SACT) for their condition. The most common treatment regimens in 1L SACT were immunotherapy (IO) combined with platinum-based chemotherapy (PBCT), PBCT alone or in combination, and IO as monotherapy or dual therapy. Specifically, pembrolizumab with carboplatin and pemetrexed was the most frequently employed regimen in the IO plus PBCT category.<br /><br />The study reports a median 1L treatment duration of 4.2 months and an average time to next treatment of 8 months. Healthcare costs during 1L SACT were high, averaging $32,215 per patient per month (PPPM), with outpatient settings accounting for 87% of these expenses. Costs were notably higher for treatments involving both IO and PBCT or IO with non-PBCT therapies, such as pembrolizumab-caboplatin-pemetrexed.<br /><br />Healthcare resource utilization (HCRU) was predominated by outpatient visits, while inpatient and emergency department visits were more frequent among patients on chemotherapy-only regimens. This underscores the significant economic burden and resource demands of treating metastatic NSCLC in real-world scenarios.<br /><br />The study acknowledges limitations, including potential administrative errors in data, underrepresentation of elderly patients with certain insurance plans, and the use of standardized cost estimates that may not reflect actual expenses. Despite these constraints, the findings provide valuable insights into treatment trends and cost implications, stressing the hefty economic burden of treating NSCLC without actionable alterations using current therapies.

Asset Subtitle

Divyan Chopra

Meta Tag

Speaker Divyan Chopra

Topic Metastatic NSCLC – Immunotherapy

Keywords

metastatic NSCLC

first-line treatment

healthcare costs

resource utilization

immunotherapy

platinum-based chemotherapy

pembrolizumab

real-world study

treatment patterns

economic burden